Antibody-drug conjugate
Antibody-drug conjugates (ADCs) are a class of targeted cancer therapeutics that combine the antigen-binding specificity of monoclonal antibodies with the cytotoxic potency of small-molecule payloads, typically linked via a chemical linker.
Antibody-drug conjugates (ADCs) are a class of targeted cancer therapeutics that combine the antigen-binding specificity of monoclonal antibodies with the cytotoxic potency of small-molecule payloads, typically linked via a chemical linker. By directing cytotoxic agents — such as camptothecin derivatives or tubulin inhibitors — to tumour-associated antigens expressed on cancer cell surfaces, ADCs aim to selectively kill malignant cells while minimizing systemic toxicity compared to conventional chemotherapy. The canonical ADC architecture consists of three components: a tumour-associated antigen-specific antibody, a cleavable or non-cleavable linker, and a cytotoxic payload that disrupts key cellular mechanisms such as mitosis and DNA replication. Upon antigen binding and internalization, cleavable linkers may be cleaved in the lysosomal compartment, whereas non-cleavable ADCs undergo lysosomal degradation of the antibody, releasing an active drug–amino-acid catabolite intracellularly. This "Trojan horse" mechanism enables delivery of highly potent agents — often too toxic for systemic administration alone — at therapeutically relevant concentrations within the tumour microenvironment.
Over the past decade, ADCs have transitioned from a niche concept to a central pillar of oncology drug development. As of the mid-2020s, twelve ADCs have received FDA approval spanning hematologic malignancies and solid tumours, including breast cancer, urothelial carcinoma, cervical cancer, and non-small cell lung cancer (NSCLC). Their clinical success has prompted broad investigation into next-generation designs featuring novel payloads, site-specific conjugation chemistries, optimized drug-to-antibody ratios (DARs), and combination strategies alongside bispecific T-cell engagers, checkpoint inhibitors, PARP inhibitors, and Cdk4/6 inhibitors.
Where the papers sit
15 papers from the last 6 months study antibody-drug conjugate directly · updated from PubMed 16 Nov 2026
Study type 0 clinical trials · 1 observational · 2 human data · 10 preclinical · 2 unclassified
Themes one subject · 1 paradigm shift · 1 new direction
Those 15 are all about one subject.
-
Targeted Cancer Therapeutics
Targeted cancer therapeutics are broadening across antigen-guided delivery, new payloads, and combination regimens rather than converging on one clinical strategy. Trop-2 ADCs are being tested in pretreated metastatic triple-negative breast cancer, while EGFR-, HER2-, and CDCP1-directed programs extend target coverage. Combination approaches include agonist anti-CD137 antibodies and optogenetic treatment platforms, with activity assessed in solid tumors. Mass spectrometry, chemoselective conjugation, proteogenomics, and safety frameworks address characterization, manufacturing, sensitization, and unexpected payload reactions.
Antibody-drug conjugates can function as initiators of antitumor immunity, not merely as targeted cytotoxic-delivery systems
The NECTIN-4- and HER2-directed ADC combination study in solid-tumor mouse models and the CD276-targeted ADC combination study in triple-negative breast cancer models found that ADC treatment contributed to immune activation beyond direct tumor-cell killing. The former showed ADC-induced immunogenic cell death, dendritic-cell cross-presentation, and dependence on cDC1s and CD8+ T cells; the latter found enhanced tumoral immunity and tumor-microenvironment remodeling alongside cytotoxicity and reported marked benefit from combining the ADC with mitochondrial gene therapy. Together, these findings replace the assumption that ADC activity is adequately described by selective payload delivery and instead make immune priming and microenvironmental effects part of the therapeutic mechanism 42561100Aug 42497865Jul.
ADC development can separate tumor localization from payload delivery and use dual targeting to address antigen heterogeneity
The next-generation ADC development concept described in “The next click in antibody drug conjugate development” assigns the ADC system a modular role in which tumor localization is decoupled from payload delivery, while dual targeting is used to address heterogeneous antigen expression. This is not simply another target or indication within conventional antibody-linked cytotoxic delivery; it proposes a different delivery architecture intended to improve pharmacokinetics and overcome heterogeneous tumor localization 42901148Oct.
Papers
The 15 papers from the last 6 months that study antibody-drug conjugate directly, newest first, by theme and by study type. Study types come from PubMed publication types and MeSH headings.
By theme
Targeted Cancer Therapeutics (15)
- Direct infusion intact mass spectrometry for rapid and sensitive characterization of antibody therapeutics in complex matrices. mAbs · 6 Nov 2026 PMID 42993286
- The next click in antibody drug conjugate development. Cell reports. Medicine · 20 Oct 2026 PMID 42901148
- A Living Multi-Omics PDX Biobank of High-Risk Sarcomas Reveals ecDNA-Driven Oncogene Amplification in Osteosarcoma and Enables Preclinical Precision Oncology. Advanced science (Weinheim, Baden-Wurttemberg, Germany) · 13 Oct 2026 PMID 42864811
- A framework for evaluating unexpected reactions in antibody-drug conjugates during clinical development: a case study of a promiscuous payload. mAbs · 16 Sept 2026 PMID 42745381
- Exploring trop-2-directed ADCs monotherapy and combination therapy in pretreated mTNBC: a real-world study. Breast cancer research and treatment · 9 Sept 2026 PMID 42714605
- CDCP1-targeted antibody-drug conjugates and immunocytokines for cancer therapy. Cancer chemotherapy and pharmacology · 16 Aug 2026 PMID 42604889
- Spatial proteogenomic profiling uncovers sensitization strategies for antibody-drug conjugate in HER2-positive breast cancer. Cell reports. Medicine · 13 Aug 2026 PMID 42594874
- EGFR-targeting ADCs: From oncogene addiction to antigen-guided drug delivery. Cancer cell · 13 Aug 2026 PMID 42594872
- The KRAS targeting revolution in metastatic pancreatic cancer: insights from the landmark RASolute-302 trial and emerging allele-specific strategies at ASCO 2026. Journal of hematology & oncology · 8 Aug 2026 PMID 42571010
- Antibody-Drug Conjugates Synergize with Agonist Anti-CD137 Monoclonal Antibodies in Solid Tumors. Cancer research · 6 Aug 2026 PMID 42561100
- Combine antibody-drug conjugate with cmLumiOpto for triple-negative breast cancer treatment. Cell reports. Medicine · 24 Jul 2026 PMID 42497865
- Q&A: Timothy Yap on Clinical Trials and Drug Development. Cancer discovery · 23 Jul 2026 PMID 42488995
- Modular Assembly of Bioconjugates Enabled by a Pyridine-Based Chemoselective Sequential Conjugation Platform. Angewandte Chemie (International ed. in English) · 8 Jul 2026 PMID 42417250
- Development of a novel humanized monoclonal antibody and efficacy profiling of site-directed antibody-drug conjugates for precision targeted therapy of CLDN18.2-positive cancers. Bioorganic chemistry · 28 Jun 2026 PMID 42365672
- Navigating first- and second-line treatment options in HR+HER2-negative advanced breast cancer. The oncologist · 10 Jun 2026 PMID 42266036
By study type
Observational studies and case reports (1)
- Exploring trop-2-directed ADCs monotherapy and combination therapy in pretreated mTNBC: a real-world study. Breast cancer research and treatment · 9 Sept 2026 PMID 42714605
Human data, design not indexed (2)
- The KRAS targeting revolution in metastatic pancreatic cancer: insights from the landmark RASolute-302 trial and emerging allele-specific strategies at ASCO 2026. Journal of hematology & oncology · 8 Aug 2026 PMID 42571010
- Q&A: Timothy Yap on Clinical Trials and Drug Development. Cancer discovery · 23 Jul 2026 PMID 42488995
Preclinical: animal, cell and lab studies (10)
- Direct infusion intact mass spectrometry for rapid and sensitive characterization of antibody therapeutics in complex matrices. mAbs · 6 Nov 2026 PMID 42993286
- The next click in antibody drug conjugate development. Cell reports. Medicine · 20 Oct 2026 PMID 42901148
- A framework for evaluating unexpected reactions in antibody-drug conjugates during clinical development: a case study of a promiscuous payload. mAbs · 16 Sept 2026 PMID 42745381
- CDCP1-targeted antibody-drug conjugates and immunocytokines for cancer therapy. Cancer chemotherapy and pharmacology · 16 Aug 2026 PMID 42604889
- Spatial proteogenomic profiling uncovers sensitization strategies for antibody-drug conjugate in HER2-positive breast cancer. Cell reports. Medicine · 13 Aug 2026 PMID 42594874
- EGFR-targeting ADCs: From oncogene addiction to antigen-guided drug delivery. Cancer cell · 13 Aug 2026 PMID 42594872
- Antibody-Drug Conjugates Synergize with Agonist Anti-CD137 Monoclonal Antibodies in Solid Tumors. Cancer research · 6 Aug 2026 PMID 42561100
- Combine antibody-drug conjugate with cmLumiOpto for triple-negative breast cancer treatment. Cell reports. Medicine · 24 Jul 2026 PMID 42497865
- Modular Assembly of Bioconjugates Enabled by a Pyridine-Based Chemoselective Sequential Conjugation Platform. Angewandte Chemie (International ed. in English) · 8 Jul 2026 PMID 42417250
- Development of a novel humanized monoclonal antibody and efficacy profiling of site-directed antibody-drug conjugates for precision targeted therapy of CLDN18.2-positive cancers. Bioorganic chemistry · 28 Jun 2026 PMID 42365672
Unclassified: not yet indexed with MeSH (2)
- A Living Multi-Omics PDX Biobank of High-Risk Sarcomas Reveals ecDNA-Driven Oncogene Amplification in Osteosarcoma and Enables Preclinical Precision Oncology. Advanced science (Weinheim, Baden-Wurttemberg, Germany) · 13 Oct 2026 PMID 42864811
- Navigating first- and second-line treatment options in HR+HER2-negative advanced breast cancer. The oncologist · 10 Jun 2026 PMID 42266036
Written from 15 PubMed abstracts, each one listed by PMID above. Published: 2026-06-15. Last written: 2026-09-18 by GPT. Corrections: 2026-09-26 by GPT. Drafted by language models from published abstracts; not medical advice.